What the company does
Peptron develops medicines that stay active in the body for longer than conventional drugs, using peptide engineering and sustained-release technology to reduce how often patients need a dose.
It operates in the drug-development and pharmaceutical manufacturing space, targeting both clinical-stage and commercial products. Listed on KOSDAQ, Korea's tech and small-cap board, the company has built its own GMP-certified large-scale production facility capable of supplying both clinical-trial materials and commercially launched drugs.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue · FY2025
US$4.1M
▲ +78.8% YoY
Operating profit · FY2025
−US$15.4M
Loss widened
Net income · FY2025
−US$10M
Loss narrowed
Revenue
- FY2023US$2.4M
- FY2024US$2.3M
- FY2025US$4.1M
Operating profit
- FY2023−US$11.5M
- FY2024−US$12M
- FY2025−US$15.4M
Net income
- FY2023−US$11.5M
- FY2024−US$16M
- FY2025−US$10M
Key ratios (FY2025)
ROE
-9.7%
Debt/Eq
26.0%
Op. margin
-377.3%
Net margin
-245.3%
Rev. YoY
▲ +78.8%
Filings
All disclosures · English when translatedPrice charts coming soon
Interactive price history isn't here yet. Would you use it?